Health implications of homocysteine and folates: Possible preventive measures

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 15, Issue 2, 2005, Pages 87-93

  Andria, Generoso ^a   Scala, Iris ^a   Sebastio, Gianfranco ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; FOLIC ACID; HOMOCYSTEINE; HORMONE; METHOTREXATE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIRTH DEFECT; CARDIOVASCULAR DISEASE; CLEFT LIP; CLEFT PALATE; CONGENITAL MALFORMATION; DIETARY INTAKE; DNA POLYMORPHISM; EDITORIAL; ENVIRONMENTAL FACTOR; FOLATE METABOLISM; FOLIC ACID DEFICIENCY; GENE INTERACTION; GENETIC RISK; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; LIMB MALFORMATION; MULTIFACTORIAL INHERITANCE; NEURAL TUBE DEFECT; OMPHALOCELE; PREVENTIVE HEALTH SERVICE; RISK FACTOR; SIDE EFFECT; URINARY TRACT MALFORMATION; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

EID: 19044367866     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2005.02.003     Document Type: Editorial

References (47)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
2. Jakubowski H. Homocysteine is a protein amino acid in humans. J Biol Chem 2002;277:30425-8.
3. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
4. Graham I, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997;277:1775-81.
5. Andria G, Fowler B, Sebastio G. Disorders of sulfur amino acid metabolism. In: Fernandes J, Saudubray J-M, van den Berghe G, Walter JH, editors. Inborn metabolic diseases - diagnosis and treatment. 3th ed. Springer; 2000. p. 223-32.
6. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common methylenetetrahydrofolate reductase mutation causes thermoinstability. Nat Genet 1995;10:111-3.
7. Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol 1999;6:359-65.
8. Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Renlund M, et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet 2003;40:619-25.
9. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leadsto hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98:2520-6.
10. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in the elderly. JAMA 1993;270:2693-8.
11. Doshi SN, McDowell IFW, Moat SJ, Payne N, Durrant HJ, Lewis MJ, Goodfellow J. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105:22-6.
12. Quinlivan EP, McPartlin J, McNulty H, Ward M, Strain JJ, Weir DG, et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 2002;359:227-8.
13. Bailey LB, Duhaney RL, Maneval DR, Kauwell GP, Quinlivan EP, Davis SR, et al. Vitamin B12 status is inversely associated with plasma homocysteine in young women with C677T and/or A1298C methylenetetrahydrofolate reductase polymorphisms. J Nutr 2002;132:1872-8.
14. Kluijtmans LAJ, Young IS, Colin A, Murray L, McMaster D, McNulty H, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003;101:2483-8.
15. Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. Eur J Obstet Gynecol Reprod Biol 1998;78:151-61.
16. Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal mulitivitamin use. Am J Epidemiol 2000;151:878-84.
17. Shaw GM, O'Malley CD, Wasserman CR, Tolarova MM, Lammer EJ. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 1995;59:536-45.
18. Scanlon KS, Ferencz C, Loffredo CA, Wilson PD, Correa-Villasenor A, Khoury MJ, et al. Preconceptional folate intake and malformations of the cardiac outflow tract. Baltimore-Washington Infant Study Group. Epidemiology 1998;9:95-8.
19. Tolarova M, Harris J. Reduced recurrence of orofacial clefts after periconceptional supplementation with high-dose folic acid and multivitamins. Teratology 1995;51:71-8.
20. Shaw GM, Lammer EJ, Wasserman CR, O'Malley CD, Tolarova MM. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. Lancet 1995;346:393-6.
21. Loffredo LC, Souza JM, Freitas JA, Mossey PA. Oral clefts and vitamin supplementation. Cleft Palate Craniofac J 2001;38:76-83.
22. Itikala PR, Watkins ML, Mulinare J, Moore CA, Liu Y. Maternal multivitamin use and orofacial clefts in offspring. Teratology 2001;63:79-86.
23. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. Am J Epidemiol 1999;150:675-82.
24. Yang Q, Khoury MJ, Olney RS, Mulinare J. Does periconceptional multivitamin use reduce the risk for limb deficiency in offspring? Epidemiology 1997;8:157-61.
25. Li DK, Daling JR, Mueller BA, Hickok DE, Fantel AG, Weiss NS. Periconceptional multivitamin use in relation to the risk of congenital urinary tract anomalies. Epidemiology 1995;6:212-8.
26. Botto LD, Mulinare J, Erickson JD. Occurrence of omphalocele in relation to maternal multivitamin use: a population-based study. Pediatrics 2002;109:904-8.
27. Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet 2004;125:12-21.
28. Hibbard ED, Smithells RW. Folic acid metabolism and human embryopathy. Lancet 1965;1:1254.
29. Medical Research Council Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-7.
30. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-5.
31. Steegers-Theunissen RPM, Boers GHJ, Trijbels JMF, Finkelstein JD, Blom HJ, Thomas CM, et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994;43:1475-80.
32. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:149-51.
33. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci U S A 1996;93:15227-32.
34. Piedrahita JA, Oetama B, Bennett GD, van Waes J, Kamen BA, Richardson J, et al. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet 1999;23:228-32.
35. Relton CL, Wilding CS, Pearce MS, Laffling AJ, Jonas PA, Lynch SA, et al. Gene-gene interaction in folate-related genes and risk of neural tube defects in a UK population. J Med Genet 2004;41:256-60.
36. Kirke PN, Mills JL, Molloy AM, Brody LC, O'Leary VB, Daly L, et al. Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. Br Med J 2004;328:1535-6.
37. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000;151:862-77.
38. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51.
39. Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999;67:317-23.
40. De Marco P, Calevo MG, Moroni A, Merello E, Raso A, Finnell RH, et al. Reduced folate carrier polymorphism (80A→G) and neural tube defects. Eur J Hum Genet 2003;11:245-52.
41. Brody LC, Conley M, Cox C, Kirke PN, McKeever MP, Mills JL, et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet 2002;71:1207-15.
42. Bailey LB, Rampersaud GC, Kauwell GPA. Folic acid supplements and fortification affect the risk for neural tube defects, vascular disease and cancer: evolving science. J Nutr 2003;133:1961S-8S.
43. CDC. Spina bifida and anencephaly before and after folic acid mandate-United States, 1995-1996 and 1999-2000. MMWR 2004;53:362-5.
44. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.
45. de Bree A, van Dusseldorp M, Brouwer IA, van het Hof KH, Steegers-Theunissen RP. Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 1997;51:643-60.
46. Yetley EA, Rader JI. Modeling the level of fortification and post-fortification assessments: US experience. Nutr Rev 2004;62:S50-9.
47. Netherlands Heart Foundation. Homocysteine and cardiovascular disease. The Hague: Netherlands Heart Foundation; 2001 (in Dutch).